Table 3. STI prevalence disaggregated by high-risk HPV category.
| STI causing organisms | Total [n/N (%)] | hrHPV + [n/N (%)] | hrHPV—[n/N (%)] | p-value |
|---|---|---|---|---|
| N | 135 | 102 | 33 | |
| MG | 2/135 (1.5) | 2/102 (2.0) | 0 | 1.0002 |
| TV | 19/135 (14.1) | 14/102 (13.7) | 5/33 (15.2) | 0.8381 |
| HD | 0 | 0 | 0 | - |
| HSV-1 | 0 | 0 | 0 | - |
| HSV-2 | 15/135 (11.1) | 11/102 (10.8) | 4/33 (12.1) | 0.8322 |
| TP | 18/135 (13.3) | 14/102 (13.7) | 4/33 (12.1) | 0.8142 |
| NG | 9/135 (6.7) | 5/102 (4.9) | 4 (12.1) | 0.1482 |
| CT-S1-CT-S2 | 11/135 (8.2) | 8/102 (7.8) | 3/33 (9.1) | 0.7302 |
| CT-S2 | 1/135 (0.7) | 1/102 (1.0) | 0 | 1.0002 |
hrHPV–high risk Human papillomavirus; MG—Mycoplasma genitalium; TV–Trichomonas vaginalis; HD–Haemophilus ducreyi; HSV-1—Herpes simplex virus type 1; HSV-2: Herpes simplex virus type 2; TP–Treponema pallidum; NG–Neisseria gonorrhoeae; CT—Chlamydia trachomatis.
p-value of ≤0.05 was considered statistically significant
p-values derived using Pearson’s Chi-squared test1 and Fisher’s Exact test2
proportions (%) for the columns reported as n/N